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Background: Because of the high incidence of drug-related problems (DRPs) among 
hospitalized patients with cardiovascular diseases and their potential impact on morbidity and 
mortality, it is important to identify the most susceptible patients, who therefore require closer 
monitoring of drug therapy.
Purpose: To identify the profile of patients at higher risk of developing at least one DRP during 
hospitalization in a cardiology ward.
Method: We consecutively included all patients hospitalized in the cardiology ward of a teach-
ing hospital in 2009. DRPs were identified through a computerized warning system designed 
by the pharmacy department and integrated into the electronic medical record.
Results: A total of 964 admissions were included, and at least one DRP was detected in 
29.8%. The variables associated with a higher risk of these events were polypharmacy (odds 
ratio [OR]=1.228; 95% confidence interval [CI]=1.153–1.308), female sex (OR=1.496; 95% 
CI=1.026–2.180), and first admission (OR=1.494; 95% CI=1.005–2.221).
Conclusion: Monitoring patients through a computerized warning system allowed the detection 
of at least one DRP in one-third of the patients. Knowledge of the risk factors for developing 
these problems in patients admitted to hospital for cardiovascular problems helps in identifying 
the most susceptible patients.
Keywords: cardiovascular diseases, patient safety, drug therapy monitoring, computerized 
provider order entry, clinical pharmacist, pharmacy warning system
Introduction
In the last few years, the use of polypharmacy has increased in patients with 
cardiovascular diseases, mainly because of the higher number of associated comor-
bidities in this patient group.1,2 Specifically, heart failure entails the management of 
multiple medical conditions, requiring a significant increase in the mean number of 
drugs from admission to discharge.2,3
A study in 62,376 patients with heart failure aged 65 years or older reported that 
the mean number and daily dose of drugs increased from 6.8 and 10.1 from April 
1998 to March 1999 to 7.5 and 11.1 from July 2000 to June 2001, respectively.4 
These increases are an inevitable consequence of the optimization of heart failure 
management. The huge complexity of drug therapy for some cardiovascular diseases 
and its high prevalence highlight the importance of adopting efficient strategies to 
closely monitor these patients.
A drug-related problem (DRP) is defined as an event or circumstance involving 
drug therapy that actually or potentially interferes with the desired health outcome.5 In 
patients with heart failure and other cardiovascular diseases, the frequency of DRPs has 
been reported to be as high as 69%6 and 78%,7 respectively. In addition, the presence of 
a DRP has been related to negative clinical outcomes.6,7 These findings demonstrate the 
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need for strategies that would allow an exhaustive review of 
drug therapy in patients with cardiovascular diseases in order 
to detect potential DRP that could trigger a health problem.
Computerized provider order entry (CPOE) is an elec-
tronic system that health care professionals can use to enter 
drugs, treatments, and test orders, and transmit the orders 
directly to the department responsible for fulfilling the 
order.8 The recent availability of these programs, which 
allow physicians to introduce prescriptions in the electronic 
medical record (EMR), and their use in routine drug therapy 
monitoring, together with pharmacy warning systems (PWS) 
that enhance safety in hospitalized patients, have helped in 
identifying DRP and their causes,9,10 thus improving the 
medication process. Nevertheless, there are patients with 
certain clinical and/or demographic characteristics who are 
at higher risk for developing a DRP and whose treatment 
needs to be more closely monitored.11,12
Some studies have identified different risk factors for 
developing at least one DRP in patients with cardiovascular 
diseases3,7 and the use of multiple medications is one of the 
variables most commonly identified.
However, most of these experiences have been developed 
in the community setting rather than in the acute clinical 
setting and have mainly focused on patients with chronic 
heart failure. To our knowledge, none have used a specific 
computerized warning system to detect potential DRPs.12 
The objective of this study was to identify the risk factors 
for the development of at least one DRP in patients admitted 
to a cardiology ward.
Materials and method
This is a prospective observational study developed from 
January to December 2009, which included patients admit-
ted to the cardiology ward of a teaching hospital with 
413 conventional beds, 18 beds for critically ill patients, and 
a catchment area of 300,000 inhabitants.13 The cardiology 
ward has approximately 30 hospital beds. We excluded 
direct admissions to the coronary unit and patients younger 
than 18 years.
Prescriptions are issued through a CPOE developed by 
a multidisciplinary team in the hospital. Likewise, the sys-
tem employed to detect potential DRP was designed by the 
pharmacy department. DRPs were classified according to the 
Pharmaceutical Care Network Europe (PCNE) classification 
for DRP version 6.2.5
The two computer applications are integrated within the 
EMR, which contain all the demographic and clinical data of 
the patient. Each time a prescription is written, the application 
generates a series of alerts (causes of potential DRPs), which 
are based on drug information and each patient’s characteris-
tics. All the alerts and prescriptions are reviewed by a team 
of clinical pharmacists. The functioning of these tools and 
data collection, diagnosis-related group, readmission, and 
anatomic therapeutic classification have been described in 
a previous study analyzing the risk factors for developing a 
DRP in patients admitted to an acute-care hospital.12
Specific definition of incorrect use  
of the CPOe in the cardiology ward
Prescription errors can result from incorrect use of the CPOE. 
An example of such errors would be the use of the free text 
comment associated with a prescription line to indicate the 
correct drug prescription by the prescriber. For example, 
acenocoumarol 4 mg/day may be prescribed, and the free text 
comment may specify that only half a tablet be administered 
on Mondays, Wednesdays, and Fridays. Acenocoumarol may 
then incorrectly appear in the nursing activities chart as 4 mg 
once-daily administration, which could lead to a DRP. This 
kind of problem is due to a lack of knowledge of the CPOE, 
which enables medication to be prescribed at intervals other 
than once-daily administration.
statistical analysis
For the descriptive analysis of the sample, categorical vari-
ables are expressed as absolute and relative frequencies and 
quantitative variables as mean and standard deviation.
A bivariate analysis of the data was performed with binary 
logistic regression, showing the odds ratio (OR) (95% con-
fidence interval [CI]), to confirm or exclude an association 
between the presence of at least one DRP during hospital 
admission with respect to each of the variables analyzed.
Subsequently, a multivariate saturated model was cal-
culated, introducing all the variables independently of their 
statistical significance in order to avoid any confounding 
factors.
The model’s discriminatory ability was verified through 
the receiver operating characteristic curve, and the Hosmer–
Lemeshow test was employed to check the calibration of 
model.
Statistical significance was set at P0.05. The statisti-
cal analysis was carried out using the SPSS 18.0 statistical 
package (IBM Corp, New York, USA).
Results
There were 16,485 admissions during the study period, of 
which 1,233 (7.48%) were admissions to the cardiology ward. 
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Of these, 266 (21.57%) were direct admissions to the 
coronary unit and three admissions (0.24%) involved 
patients younger than 18 years. After application of the 
exclusion criteria, 964 (78.18%) admissions were included 
in this study.
The 964 admissions corresponded to 842 patients 
(1.14 admissions/patient) (range: 1–4). The mean age was 
68.7 years (SD: 13.5) (range: 20–95), and 588 (61.0%) were 
men. At least one DRP was identified in 287 admissions 
(29.8%); in these admissions, the mean number of DRPs 
was 1.87 (SD: 1.19).
When the 842 patients were considered, at least one DRP 
was detected in 259 of them (30.8%).
A total of 8,923 drug prescriptions were issued 
during the study period, with a mean of 9.25 (SD: 4.99) 
prescriptions/admission. One or more DRP was identi-
fied in 516 drug prescriptions (5.78%). Among these, the 
mean of prescriptions with a DRP per admission was 1.80 
(SD: 1.08).
In all, 448 DRPs were detected, mainly involving drug–
drug or drug–food interactions, prescription errors due to 
inadequate knowledge of the use of the CPOE, prescription 
of an inappropriate dose for a specific drug, inappropriate 
dosing schedule, or dose adjustment due to a change in renal 
function (Table 1).
The distribution of the main DRP according to the cardiac 
disease present in admitted patients is shown in Table 2.
The bivariate and multivariate analyses of the demographic 
and clinical characteristics of the admitted patients with one 
or more DRP compared with patients free of these events 
are shown in Table 3.
None of the patients had underlying liver failure or 
cachexia. The mean length of hospital stay was 9.58 days 
(SD: 8.21) in patients with at least one DRP versus 5.03 days 
(SD: 4.96) in those without DRP (P0.001). Among patients 
with at least one DRP, seven died (2.70%) versus eight 
(1.37%) among those with no DRP (P=0.256).
In the logistic regression analysis, the factors sig-
nificantly associated with the occurrence of at least one 
DRP were each additional drug received (OR=1.228; 
95% CI=1.153–1.308), female sex (OR=1.496; 95% 
CI=1.026–2.180), and first admission (OR=1.494; 95% 
CI=1.005–2.221).
In the multivariate model, the area under the curve (AUC) 
value of the receiver operating characteristic curve was 0.788 
(95% CI=0.756–0.820).
Calibration of the model by the Hosmer–Lemeshow test 
showed no statistical significance (P=0.458), indicating that 
the model was correctly calibrated.
Discussion
This study aimed to determine the factors associated with 
an increased risk of developing one or more DRP during 
hospital admission in patients with cardiovascular disease. 
Table 1 Distribution of the type of DRPs detected
Primary domain Cause Total DRP n=448 (%)
Drug selection inappropriate drug (including contraindicated) 10 (2.23)
no indication for the drug 2 (0.45)
inappropriate combination of drugs, or drugs and food 87 (19.42)
inappropriate duplication of therapeutic group or active ingredient 8 (1.79)
indication for drug therapy not noticed 14 (3.13)
More cost-effective drug available 5 (1.12)
Dosage form inappropriate dosage form 2 (0.45)
Dose selection Drug dose too low 30 (6.70)
Drug dose too high 41 (9.15)
Dosage regimen not frequent enough 4 (0.89)
Dosage regimen too frequent 60 (13.39)
no therapeutic drug monitoring 2 (0.45)
Pharmacokinetic problem requiring dose adjustment 50 (11.16)
Treatment length Treatment length too long 1 (0.22)
Drug use process inappropriate timing of administration and/or dosing intervals 3 (0.67)
inappropriate mode of administration 12 (2.68)
logistics Prescription errors due to incorrect use of the CPOe 78 (17.41)
Other no monitoring of analytic parameters susceptible to being altered by the drug 1 (0.22)
alteration of analytic parameters by the drug 13 (2.90)
Prescription of a drug not included in the hospital formulary 25 (5.58)
Abbreviations: CPOe, computerized provider order entry; DRP, drug-related problem.





We found that one of the variables associated with a higher 
risk of having at least one DRP was the number of drugs 
prescribed during hospital admission, with each additional 
drug representing a 22% increase in risk. This finding has 
been previously reported. A study of 91 patients attending 
the emergency department with a primary diagnosis of heart 
failure found a significant correlation between polypharmacy 
and medication errors, as well as between the number of 
drugs prescribed and drug–drug interactions, interactions 
due to renal insufficiency, liver failure, or both.3 Another 
study of 97 patients with heart failure found a positive cor-
relation between the number of drugs and the number of 
DRPs.7 Other studies, although not specifically related to 
cardiovascular disease, have found a significant correlation 
between the number of drugs prescribed and the risk of DRP 
in hospitalized patients14 and the risk of adverse drug reac-
tions in elderly in-hospital patients.11
In the present study, certain cardiovascular diseases, such 
as heart failure and ischemic heart disease, were associated 
with a higher risk of developing at least one DRP in the 
bivariate analysis. Nevertheless, this association was not 
maintained in the multivariate analysis. In contrast, another 
study identified an association between heart failure and 
a higher risk of adverse drug reactions in older patients 
(OR=1.79; 95% CI=1.39–2.30).11 However, that study did 
not compare the risk of developing DRPs among distinct 
cardiovascular diseases.
Among demographic variables in our study, only 
female sex was associated with a higher risk of developing 
at least one DRP. Similarly, a study of 1,857 patients with 
chronic heart failure reported that female patients were less 
frequently treated with required drugs, such as angiotensin 
converting-enzyme inhibitors or angiotensin II receptor 
blockers, and were less frequently prescribed adequate doses 
of β-blockers.15 In contrast, other studies have found no rela-
tionship between age or sex and the frequency of DRP in heart 
transplant recipients,16 or between demographic variables and 
a higher number of drugs in patients with heart failure.3
Another variable associated with DRP in our study was 
not having had a prior admission. A possible explanation 
for this finding is that patients with prior admissions might 
have undergone an exhaustive medication review, which 
could have prevented some DRPs.17 Clarification of the role 
of medication reviews in preventing DRPs may be provided 
by a controlled clinical trial aiming to evaluate the effects 
of a medication review and cognitive behavioral therapy 
carried out by community pharmacists on the DRP rate in 
elderly patients discharged from hospital, but the results of 
this study are still pending.17
In the present study, we found no association between 
the risk of DRP and administration of drugs in certain thera-
peutic groups. Nevertheless, a prior study evaluated adverse 
drug events in patients admitted to two tertiary hospitals. In 
a cohort analysis of patients admitted to one of the hospi-
tals, risk factors for DRPs were administration of diuretics 
(OR=1.7; 95% CI=1.0–2.6) and electrolyte concentrates 
(OR=1.7; 95% CI=1.1–2.5). In a case–control analysis of 
patients admitted to both hospitals, exposure to psychoac-
tive drugs was identified as a risk factor (OR=2.1; 95% 
CI=1.3–3.6).18 Although administration of cardiovascular 
drugs was an independent predictor of serious adverse events 
in the case–control analysis (OR=2.4; 95% CI=1.3–4.5), 
the authors considered this to be a chance finding for two 
possible reasons: this therapeutic class was an infrequent 
cause of events and their administration could be a marker 
of an underlying condition.
Numerous studies have demonstrated that multidisci-
plinary management reduces admission rates and overall 
Table 2 Distribution of the main causes of DRPs by type of heart disease











inappropriate combination  
of drugs or food and drugs
48 (22.1%) 1 (7.1%) 27 (19.4%) 10 (14.2%) 1 (14.3%) 0.530
Drug dose too low 13 (6.0%) 1 (7.1%) 11 (7.9%) 5 (7.1%) 0 (0%) 0.894
Drug dose too high 16 (7.3%) 0 (0%) 12 (8.6%) 12 (17.1%) 1 (14.3%) 0.102
Dosage regimen too frequent 22 (10.1%) 0 (0%) 27 (19.4%) 11 (15.7%) 0 (0%) 0.053
Dose adjustment according 
to renal function
38 (17.4%) 2 (14.3%) 7 (5.0%) 4 (5.7%) 1 (14.3%) 0.002
Prescription errors due to 
incorrect use of the CPOe
27 (12.4%) 4 (28.5%) 30 (21.6%) 15 (21.5%) 2 (28.6%) 0.049
Other 54 (24.7%) 6 (43%) 25 (18.1%) 13 (18.7%) 2 (28.6%) 0.154
Total DRPs 218 (100%) 14 (100%) 139 (100%) 70 (100%) 7 (100%) –
Abbreviations: CPOe, computerized provider order entry; DRP, drug-related problem.
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mortality in patients with chronic cardiovascular diseases 
such as heart failure.19–24 In our study, the mean length of 
hospital stay was more than 4 days longer in patients with at 
least one DRP than in those without. Because of the economic 
impact of prolonged hospital stays,25–27 this topic should be 
studied in greater depth.
In the present study, at least one DRP was detected in 
approximately 30% of admissions. This percentage is lower 
than that reported in other studies in patients with cardiovas-
cular diseases.6,7 In one of these studies, 69% of 85 outpatients 
with cardiovascular disease had at least one DRP.6 In another 
study, 78% of 97 patients with heart failure managed in an 
outpatient clinic had a drug-related negative outcome or 
showed a risk of a drug-related negative outcome.7 However, 
both studies were performed in a non-hospital outpatient 
setting, where the medication was checked by a pharmacist 
daily. Another study reported that 40% (19 of 48) of read-
missions in patients who had previously received a heart 
transplant were caused by DRPs and that 58% (11 of 19) of 
these were preventable.16 These values are closer to those 
observed in our study.
The most frequent types of DRP identified in this study 
were interactions, prescription errors caused by inadequate 
knowledge of the CPOE, prescription of an inappropriate 
dose or frequency of administration, and dose adjustment 
according to renal function. A study of 97 patients with heart 
Table 3 Bivariate and multivariate model of the demographic and clinical characteristics of admissions with at least one DRP versus 
those with no DRP
Variable Bivariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
sex (female) 1.28 (0.97–1.70) 0.082 1.50 (1.03–2.18) 0.036
age (per year) 1.03 (1.02–1.04) 0.001 1.00 (0.99–1.02) 0.778
Charlson index
0 1 (ref) 1 (ref)
1 2.42 (1.32–4.42) 0.004 1.52 (0.78–2.96) 0.218
2 3.32 (2.08–5.30) 0.001 1.48 (0.85–2.59) 0.169
Urgent admission 0.45 (0.34–0.61) 0.001 1.42 (0.90–2.25) 0.130
surgical admission 0.76 (0.56–1.03) 0.073 0.98 (0.59–1.62) 0.935
First admission 0.67 (0.50–0.89) 0.007 1.49 (1.00–2.22) 0.047
DRg weight 1.09 (0.99–1.20) 0.080 0.98 (0.84–1.15) 0.824
number of drugs during admission 1.24 (1.20–1.28) 0.001 1.23 (1.15–1.31) 0.001
heart disease
Valvular heart disease 1 (ref) 1 (ref)
heart failure 3.55 (1.46–8.64) 0.005 0.89 (0.31–2.58) 0.835
ischemic heart disease 2.58 (1.06–6.33) 0.038 1.52 (0.53–4.36) 0.432
arrhythmias 1.96 (0.78–4.92) 0.149 1.59 (0.54–4.69) 0.405
Other 1.14 (0.32–4.13) 0.840 0.82 (0.18–3.65) 0.797
Obesity 1.52 (0.93–2.49) 0.097 1.41 (0.78–2.53) 0.251
Renal insufficiency 2.62 (1.84–3.74) 0.001 1.19 (0.76–1.85) 0.449
aTC group
a: alimentary tract and metabolism 3.38 (2.34–4.87) 0.001 1.24 (0.80–1.93) 0.332
B: Blood and hematopoyetic organs 3.74 (2.11–6.65) 0.001 1.23 (0.61–2.46) 0.562
C: Cardiovascular system 6.13 (2.20–17.10) 0.001 1.58 (0.50–4.93) 0.433
D: Dermatological therapy 3.56 (0.59–21.45) 0.165 – –
g: genitourinary treatment (including sex hormones) 2.52 (1.49–4.26) 0.001 1.38 (0.72–2.63) 0.333
h: hormone therapy 1.93 (1.21–3.09) 0.006 0.82 (0.46–1.46) 0.509
J: anti-infective therapy, systemic use 2.51(1.85–3.40) 0.001 1.26 (0.81–1.97) 0.312
l: antineoplastic therapy and immunomodulatory agents 3.98 (0.95–16.78) 0.060 3.47 (0.71–17.04) 0.126
M: Musculoskeletal system 2.21 (1.43–3.41) 0.001 1.30 (0.77–2.19) 0.319
n: nervous system 1.99 (1.42–2.77) 0.001 0.94 (0.62–1.44) 0.788
P: antiparasitic products, insecticides,  
and repellants
2.36 (0.15–37.92) 0.54 – –
R: Respiratory system 3.74 (2.77–5.04) 0.001 1.39 (0.94–2.06) 0.095
s: sensory organs 5.86 (2.65–12.96) 0.001 3.20 (0.84–12.13) 0.087
V: Various 5.86 (2.05–16.80) 0.001 0.95 (0.16–5.60) 0.953
Abbreviations: ATC, anatomical therapeutic chemical; CI, confidence interval; DRG, diagnosis-related group; DRP, drug-related problem; OR, odds ratio; ref, reference 
category.





failure found that one of the most frequent DRP detected 
(22%) involved inadequate dose, regimen, or duration of a 
drug,7 while a study of 19 heart transplant recipients who 
were readmitted for a DRP found that the most common 
cause was an inappropriate dose (47.4%).16 In our study, dose 
adjustment according to renal function was more frequent 
in patients with heart failure than in those with other car-
diovascular diseases. In contrast, prescription errors caused 
by inadequate knowledge of the CPOE were less frequent 
in patients with heart failure than in those with other cardio-
vascular diseases.
Among the limitations of this study is the impossibility 
of determining the association between the DRP detected 
by the PWS designed by the pharmacy department and 
health outcomes. In addition, we did not evaluate the effect 
of the DRP rate due to admission of patients with cardio-
vascular diseases in units other than the cardiology ward. 
Finally, when the study was being performed, the pharmacy 
application contained information on 82.3% of the active 
ingredients available in the hospital, which could have led 
to nondetection of DRPs related to drugs not included in the 
information in the system. Nevertheless, this percentage of 
drugs represented 99% of the prescriptions issued during 
the study period.
A strength of this study is that the DRP warning sys-
tem contained data on a large number of drugs as well as 
information on diagnostic and laboratory tests. Unlike other 
studies, in addition to including renal function, this study 
also included analysis of other physiological conditions 
that could alter the pharmacokinetics of the drugs used in 
cardiovascular disease, such as liver failure, cachexia, and 
obesity. Moreover, we included 964 patients admitted to 
hospital with cardiovascular disease, a sample that is much 
larger than that included in other studies.
Several authors have highlighted the need to equip pre-
scription and medication review systems with utilities to 
integrate all the valuable information (demographic, clini-
cal, and pharmacological conditions).28 Identifying the risk 
factors for DRP in patients with cardiovascular disease in an 
acute setting could facilitate the design and implementation of 
a specific predictive model in our EMR to rapidly detect the 
profile of these patients. Because daily medication reviews 
of all hospitalized patients is extremely time consuming, an 
efficient screening tool to identify patients at highest risk 
of DRP would enable clinical pharmacists to prioritize and 
optimize their work flow.
In conclusion, this study identified the number of drugs, 
female sex, and first admission as the risk predictors for 
developing DRPs in patients with cardiovascular diseases 
in a cardiology ward.
As proposed by other authors,28 early identification of 
patients most at risk for DRPs during admission could aid 
closer monitoring, which could in turn lead to improved 
clinical, economic, and humanistic outcomes.
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